Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis
Osteoarthritis (OA) is a degenerative joint disease that causes pain and bone deterioration driven by an increase in prostaglandins (PGs) and inflammatory cytokines. Current treatments focus on inhibiting prostaglandin production, a pro-inflammatory lipid metabolite, with NSAID drugs; however, other...
Saved in:
Main Authors: | Cindy B. McReynolds (Author), Sung Hee Hwang (Author), Jun Yang (Author), Debin Wan (Author), Karen Wagner (Author), Christophe Morisseau (Author), Dongyang Li (Author), William K. Schmidt (Author), Bruce D. Hammock (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea
by: Debin Wan, et al.
Published: (2019) -
Soluble Epoxide Hydrolase Deletion Limits High-Fat Diet-Induced Inflammation
by: Karen M. Wagner, et al.
Published: (2021) -
2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity
by: Juan Martín-López, et al.
Published: (2021) -
Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors
by: John D. Imig, et al.
Published: (2020) -
Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers
by: William K. Schmidt, et al.
Published: (2024)